Date of Award
2018
Document Type
Thesis
Department
Chemistry
First Reader
Dr. Joseph Bradshaw
Second Reader
Dr. B. Allyson Phillips
Third Reader
Dr. Johnny Wink
Abstract
Photodynamic therapy (PDT) is a relatively new treatment option in medicine including treating some types of cancers. PDT utilizes light to activate small molecules for treatment. Some of these molecules used as PDT agents are porphyrin derivatives. While PDT is currently being used in the fight against cancer, it has several limitations and is currently being used in conjunction with chemotherapy and/or radiation in order to be effective. This research focused on synthesizing a new zinc (II) porphyrin and incorporating a fluorescent sulfocycline and testing the compound on the MB 231 breast cancer cell line.
Once the metallated porphyrin was synthesized and purified, IR, UV-vis, fluorescence, and NMR spectroscopies were run to characterize the compound. Once this data was collected, the compound was tested on the MB231 cell line. The MB231 cell line is also referred to as triple negative breast cancer cells. After cells were treated with the metallated porphyrin an MTI assay was run to look at cell viability in both light and dark conditions.
Along with the testing of the synthesized metallated porphyrin, research was done on how patient attitude has been shown to effect patient outcome. While looking at this, cancer patients were focused on. In order to increase the number of available cases, other diseases were looked at as well.
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Recommended Citation
Thomas, Kaitlyn, "Killing Cancer with Light" (2018). Honors Theses. 660.
https://scholarlycommons.obu.edu/honors_theses/660